Burning Rock Biotech Limited (NASDAQ: BNR) Stock Competitors & Peer Comparison
See BNR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BNR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BNR | $16.25 | +1.63% | 17.3M | -18.84 | -$0.87 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.71% |
| TMO | $654.80 | +0.35% | 242.2B | 28.28 | $23.16 | +0.28% |
| DHR | $214.06 | +1.09% | 150.5B | 26.82 | $7.98 | +0.71% |
| NTRA | $410.35 | +0.46% | 58.8B | -310.87 | -$1.32 | N/A |
| A | $167.78 | +0.66% | 47.4B | 28.86 | $5.81 | +0.60% |
| IQV | $258.21 | -0.96% | 42.5B | 21.29 | $12.13 | N/A |
| WAT | $425.21 | -0.08% | 41.7B | 31.08 | $13.68 | N/A |
| ILMN | $273.04 | +2.75% | 41.3B | 54.28 | $5.03 | N/A |
| IDXX | $518.39 | +0.12% | 40.9B | 36.45 | $14.22 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
BNR vs DHR-PB Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, BNR's ROE is -0.13%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, BNR is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for BNR.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
BNR vs TMO Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, TMO has a market cap of 242.2B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while TMO trades at $654.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas TMO's P/E ratio is 28.28. In terms of profitability, BNR's ROE is -0.13%, compared to TMO's ROE of +0.13%. Regarding short-term risk, BNR is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for BNR.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
BNR vs DHR Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, DHR has a market cap of 150.5B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while DHR trades at $214.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas DHR's P/E ratio is 26.82. In terms of profitability, BNR's ROE is -0.13%, compared to DHR's ROE of +0.08%. Regarding short-term risk, BNR is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for BNR.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
BNR vs NTRA Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, NTRA has a market cap of 58.8B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while NTRA trades at $410.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas NTRA's P/E ratio is -310.87. In terms of profitability, BNR's ROE is -0.13%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, BNR is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for BNR.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
BNR vs A Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, A has a market cap of 47.4B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while A trades at $167.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas A's P/E ratio is 28.86. In terms of profitability, BNR's ROE is -0.13%, compared to A's ROE of +0.20%. Regarding short-term risk, BNR is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for BNR.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
BNR vs IQV Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, IQV has a market cap of 42.5B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while IQV trades at $258.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas IQV's P/E ratio is 21.29. In terms of profitability, BNR's ROE is -0.13%, compared to IQV's ROE of +0.22%. Regarding short-term risk, BNR is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for BNR.Check IQV's competition here
Waters Corporation (NYSE: WAT)
BNR vs WAT Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, WAT has a market cap of 41.7B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while WAT trades at $425.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas WAT's P/E ratio is 31.08. In terms of profitability, BNR's ROE is -0.13%, compared to WAT's ROE of +0.02%. Regarding short-term risk, BNR is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for BNR.Check WAT's competition here
Illumina, Inc. (NASDAQ: ILMN)
BNR vs ILMN Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, ILMN has a market cap of 41.3B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while ILMN trades at $273.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas ILMN's P/E ratio is 54.28. In terms of profitability, BNR's ROE is -0.13%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, BNR is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for BNR.Check ILMN's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
BNR vs IDXX Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, IDXX has a market cap of 40.9B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while IDXX trades at $518.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas IDXX's P/E ratio is 36.45. In terms of profitability, BNR's ROE is -0.13%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, BNR is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for BNR.Check IDXX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
BNR vs MTD Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, MTD has a market cap of 30B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while MTD trades at $1,486.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas MTD's P/E ratio is 34.17. In terms of profitability, BNR's ROE is -0.13%, compared to MTD's ROE of -12.00%. Regarding short-term risk, BNR is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for BNR.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
BNR vs DGX Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, DGX has a market cap of 25.7B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while DGX trades at $233.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas DGX's P/E ratio is 23.00. In terms of profitability, BNR's ROE is -0.13%, compared to DGX's ROE of +0.14%. Regarding short-term risk, BNR is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for BNR.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
BNR vs LH Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, LH has a market cap of 25.3B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while LH trades at $308.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas LH's P/E ratio is 18.31. In terms of profitability, BNR's ROE is -0.13%, compared to LH's ROE of +0.12%. Regarding short-term risk, BNR is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for BNR.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
BNR vs GH Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, GH has a market cap of 23.9B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while GH trades at $177.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas GH's P/E ratio is -50.95. In terms of profitability, BNR's ROE is -0.13%, compared to GH's ROE of +2.11%. Regarding short-term risk, BNR is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for BNR.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
BNR vs EXAS Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas EXAS's P/E ratio is -95.37. In terms of profitability, BNR's ROE is -0.13%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, BNR is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for BNR.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
BNR vs ILMNV Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas ILMNV's P/E ratio is N/A. In terms of profitability, BNR's ROE is -0.13%, compared to ILMNV's ROE of N/A. Regarding short-term risk, BNR is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for BNR.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
BNR vs RVTY Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, RVTY has a market cap of 16.9B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while RVTY trades at $151.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas RVTY's P/E ratio is 28.30. In terms of profitability, BNR's ROE is -0.13%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, BNR is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for BNR.Check RVTY's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
BNR vs MEDP Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, MEDP has a market cap of 16.7B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while MEDP trades at $599.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas MEDP's P/E ratio is 35.14. In terms of profitability, BNR's ROE is -0.13%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, BNR is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for BNR.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
BNR vs PKI Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas PKI's P/E ratio is 41.45. In terms of profitability, BNR's ROE is -0.13%, compared to PKI's ROE of +0.03%. Regarding short-term risk, BNR is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for BNR.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
BNR vs CRL Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, CRL has a market cap of 14B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while CRL trades at $290.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas CRL's P/E ratio is 29.31. In terms of profitability, BNR's ROE is -0.13%, compared to CRL's ROE of -0.08%. Regarding short-term risk, BNR is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for BNR.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
BNR vs ICLR Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, ICLR has a market cap of 12.4B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while ICLR trades at $162.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas ICLR's P/E ratio is 13.22. In terms of profitability, BNR's ROE is -0.13%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, BNR is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for BNR.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
BNR vs QGEN Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, QGEN has a market cap of 9.2B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while QGEN trades at $44.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas QGEN's P/E ratio is 18.49. In terms of profitability, BNR's ROE is -0.13%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, BNR is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for BNR.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
BNR vs GRAL Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, GRAL has a market cap of 5.7B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while GRAL trades at $143.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas GRAL's P/E ratio is -13.60. In terms of profitability, BNR's ROE is -0.13%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, BNR is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for BNR.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
BNR vs RDNT Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, RDNT has a market cap of 5.5B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while RDNT trades at $69.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas RDNT's P/E ratio is 152.02. In terms of profitability, BNR's ROE is -0.13%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, BNR is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for BNR.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
BNR vs SHC Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while SHC trades at $18.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas SHC's P/E ratio is 18.98. In terms of profitability, BNR's ROE is -0.13%, compared to SHC's ROE of +0.27%. Regarding short-term risk, BNR is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for BNR.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
BNR vs BLLN Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, BLLN has a market cap of 4.9B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while BLLN trades at $105.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas BLLN's P/E ratio is 151.29. In terms of profitability, BNR's ROE is -0.13%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, BNR is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for BNR.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
BNR vs SYNH Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas SYNH's P/E ratio is 61.40. In terms of profitability, BNR's ROE is -0.13%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, BNR is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for BNR.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
BNR vs VCYT Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, VCYT has a market cap of 3.7B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while VCYT trades at $45.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas VCYT's P/E ratio is 22.91. In terms of profitability, BNR's ROE is -0.13%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, BNR is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for BNR.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
BNR vs CDNA Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, CDNA has a market cap of 3.5B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while CDNA trades at $67.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas CDNA's P/E ratio is 79.94. In terms of profitability, BNR's ROE is -0.13%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, BNR is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for BNR.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
BNR vs OLK Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas OLK's P/E ratio is -96.59. In terms of profitability, BNR's ROE is -0.13%, compared to OLK's ROE of -0.07%. Regarding short-term risk, BNR is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for BNR.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
BNR vs WGS Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, WGS has a market cap of 2.2B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while WGS trades at $73.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas WGS's P/E ratio is 203.03. In terms of profitability, BNR's ROE is -0.13%, compared to WGS's ROE of -0.39%. Regarding short-term risk, BNR is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for BNR.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
BNR vs PSNL Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while PSNL trades at $16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas PSNL's P/E ratio is -14.94. In terms of profitability, BNR's ROE is -0.13%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, BNR is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for BNR.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
BNR vs OPK Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while OPK trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas OPK's P/E ratio is -5.78. In terms of profitability, BNR's ROE is -0.13%, compared to OPK's ROE of -0.06%. Regarding short-term risk, BNR is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for BNR.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
BNR vs CSTL Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while CSTL trades at $35.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas CSTL's P/E ratio is -53.88. In terms of profitability, BNR's ROE is -0.13%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, BNR is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for BNR.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
BNR vs FLGT Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, FLGT has a market cap of 610M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while FLGT trades at $21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas FLGT's P/E ratio is 2148.00. In terms of profitability, BNR's ROE is -0.13%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, BNR is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for BNR.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
BNR vs GRALV Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas GRALV's P/E ratio is N/A. In terms of profitability, BNR's ROE is -0.13%, compared to GRALV's ROE of N/A. Regarding short-term risk, BNR is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for BNR.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
BNR vs NEO Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, NEO has a market cap of 474.6M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while NEO trades at $18.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas NEO's P/E ratio is 142.08. In terms of profitability, BNR's ROE is -0.13%, compared to NEO's ROE of -0.06%. Regarding short-term risk, BNR is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for BNR.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
BNR vs MYGN Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, MYGN has a market cap of 428.8M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while MYGN trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas MYGN's P/E ratio is -34.92. In terms of profitability, BNR's ROE is -0.13%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, BNR is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for BNR.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
BNR vs CO Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas CO's P/E ratio is 5.06. In terms of profitability, BNR's ROE is -0.13%, compared to CO's ROE of +0.11%. Regarding short-term risk, BNR is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for BNR.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
BNR vs FLDM Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas FLDM's P/E ratio is -4.74. In terms of profitability, BNR's ROE is -0.13%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, BNR is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for BNR.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
BNR vs BDSX Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, BDSX has a market cap of 225.6M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while BDSX trades at $27.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas BDSX's P/E ratio is -8.74. In terms of profitability, BNR's ROE is -0.13%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, BNR is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for BNR.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
BNR vs XGN Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, XGN has a market cap of 197.4M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while XGN trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas XGN's P/E ratio is -10.09. In terms of profitability, BNR's ROE is -0.13%, compared to XGN's ROE of -1.22%. Regarding short-term risk, BNR is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for BNR.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
BNR vs FRNM Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, FRNM has a market cap of 133.1M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while FRNM trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas FRNM's P/E ratio is N/A. In terms of profitability, BNR's ROE is -0.13%, compared to FRNM's ROE of N/A. Regarding short-term risk, BNR is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for BNR.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
BNR vs GTH Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas GTH's P/E ratio is -1.11. In terms of profitability, BNR's ROE is -0.13%, compared to GTH's ROE of -1.01%. Regarding short-term risk, BNR is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for BNR.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
BNR vs GENE Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas GENE's P/E ratio is -38.25. In terms of profitability, BNR's ROE is -0.13%, compared to GENE's ROE of -1.85%. Regarding short-term risk, BNR is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for BNR.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
BNR vs IMDX Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, IMDX has a market cap of 111.1M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while IMDX trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas IMDX's P/E ratio is -2.31. In terms of profitability, BNR's ROE is -0.13%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, BNR is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for BNR.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
BNR vs SERA Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, SERA has a market cap of 79.1M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while SERA trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas SERA's P/E ratio is -3.18. In terms of profitability, BNR's ROE is -0.13%, compared to SERA's ROE of -0.47%. Regarding short-term risk, BNR is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for BNR.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
BNR vs PRPO Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, PRPO has a market cap of 41.3M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while PRPO trades at $23.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas PRPO's P/E ratio is -35.58. In terms of profitability, BNR's ROE is -0.13%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, BNR is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for BNR.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
BNR vs QUCY Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, QUCY has a market cap of 30.5M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while QUCY trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas QUCY's P/E ratio is -0.06. In terms of profitability, BNR's ROE is -0.13%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, BNR is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for BNR.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
BNR vs MDXH Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, MDXH has a market cap of 29.3M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while MDXH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas MDXH's P/E ratio is -0.78. In terms of profitability, BNR's ROE is -0.13%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, BNR is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for BNR.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
BNR vs AKU Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas AKU's P/E ratio is -0.13. In terms of profitability, BNR's ROE is -0.13%, compared to AKU's ROE of -5.32%. Regarding short-term risk, BNR is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for BNR.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
BNR vs CEMI Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas CEMI's P/E ratio is -0.63. In terms of profitability, BNR's ROE is -0.13%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, BNR is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for BNR.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
BNR vs ENZ Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas ENZ's P/E ratio is -2.24. In terms of profitability, BNR's ROE is -0.13%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, BNR is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for BNR.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
BNR vs PMD Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas PMD's P/E ratio is -5.24. In terms of profitability, BNR's ROE is -0.13%, compared to PMD's ROE of -0.32%. Regarding short-term risk, BNR is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for BNR.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
BNR vs ME Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas ME's P/E ratio is -0.03. In terms of profitability, BNR's ROE is -0.13%, compared to ME's ROE of -42.03%. Regarding short-term risk, BNR is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for BNR.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
BNR vs MYNZ Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, BNR's ROE is -0.13%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, BNR is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for BNR.Check MYNZ's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
BNR vs BIAFW Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, BIAFW has a market cap of 11.8M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while BIAFW trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas BIAFW's P/E ratio is 1.25. In terms of profitability, BNR's ROE is -0.13%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, BNR is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for BNR.Check BIAFW's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
BNR vs CHEK Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas CHEK's P/E ratio is -0.43. In terms of profitability, BNR's ROE is -0.13%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, BNR is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for BNR.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
BNR vs CNTG Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas CNTG's P/E ratio is -0.23. In terms of profitability, BNR's ROE is -0.13%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, BNR is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for BNR.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
BNR vs ADVB Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, ADVB has a market cap of 9.3M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while ADVB trades at $6.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas ADVB's P/E ratio is -61.00. In terms of profitability, BNR's ROE is -0.13%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, BNR is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for BNR.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
BNR vs NDRA Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while NDRA trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas NDRA's P/E ratio is -0.90. In terms of profitability, BNR's ROE is -0.13%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, BNR is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for BNR.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
BNR vs APDN Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas APDN's P/E ratio is -0.10. In terms of profitability, BNR's ROE is -0.13%, compared to APDN's ROE of -7.23%. Regarding short-term risk, BNR is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for BNR.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
BNR vs NVTA Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas NVTA's P/E ratio is -0.00. In terms of profitability, BNR's ROE is -0.13%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, BNR is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for BNR.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
BNR vs LMDXW Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, BNR's ROE is -0.13%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, BNR is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for BNR.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
BNR vs LMDX Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas LMDX's P/E ratio is -0.01. In terms of profitability, BNR's ROE is -0.13%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, BNR is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for BNR.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
BNR vs DMTK Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas DMTK's P/E ratio is -0.04. In terms of profitability, BNR's ROE is -0.13%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, BNR is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for BNR.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
BNR vs NOTV Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas NOTV's P/E ratio is -0.03. In terms of profitability, BNR's ROE is -0.13%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, BNR is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for BNR.Check NOTV's competition here
iSpecimen Inc. (NASDAQ: ISPC)
BNR vs ISPC Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, ISPC has a market cap of 2.6M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while ISPC trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas ISPC's P/E ratio is -0.03. In terms of profitability, BNR's ROE is -0.13%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, BNR is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for BNR.Check ISPC's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
BNR vs BIAF Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, BIAF has a market cap of 2.5M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while BIAF trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas BIAF's P/E ratio is -0.71. In terms of profitability, BNR's ROE is -0.13%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, BNR is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for BNR.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
BNR vs SQL Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas SQL's P/E ratio is -0.40. In terms of profitability, BNR's ROE is -0.13%, compared to SQL's ROE of -30.46%. Regarding short-term risk, BNR is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for BNR.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
BNR vs AWH Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas AWH's P/E ratio is -0.09. In terms of profitability, BNR's ROE is -0.13%, compared to AWH's ROE of +1.62%. Regarding short-term risk, BNR is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for BNR.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
BNR vs HTGM Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas HTGM's P/E ratio is -0.03. In terms of profitability, BNR's ROE is -0.13%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, BNR is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for BNR.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
BNR vs BIOC Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas BIOC's P/E ratio is -0.01. In terms of profitability, BNR's ROE is -0.13%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, BNR is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for BNR.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
BNR vs SQLLW Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, BNR's ROE is -0.13%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, BNR is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for BNR.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
BNR vs WGSWW Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, BNR's ROE is -0.13%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, BNR is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for BNR.Check WGSWW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
BNR vs NDRAW Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas NDRAW's P/E ratio is N/A. In terms of profitability, BNR's ROE is -0.13%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, BNR is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for BNR.Check NDRAW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
BNR vs PRXL Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas PRXL's P/E ratio is 42.97. In terms of profitability, BNR's ROE is -0.13%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, BNR is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for BNR.Check PRXL's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
BNR vs OCDX Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas OCDX's P/E ratio is -42.28. In terms of profitability, BNR's ROE is -0.13%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, BNR is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for BNR.Check OCDX's competition here
Danaher Corporation (NYSE: DHR-PA)
BNR vs DHR-PA Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, BNR's ROE is -0.13%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, BNR is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for BNR.Check DHR-PA's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
BNR vs BNGOW Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas BNGOW's P/E ratio is N/A. In terms of profitability, BNR's ROE is -0.13%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, BNR is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for BNR.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
BNR vs CHEKZ Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, BNR's ROE is -0.13%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, BNR is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for BNR.Check CHEKZ's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
BNR vs MEUSW Comparison October 2026
Burning Rock Biotech Limited (NASDAQ: BNR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BNR stands at 17.3M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, BNR is priced at $16.25 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BNR currently has a P/E ratio of -18.84, whereas MEUSW's P/E ratio is N/A. In terms of profitability, BNR's ROE is -0.13%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, BNR is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for BNR.Check MEUSW's competition here